SonoMotion receives FDA IDE approval to initiate its Break Wave™ First-In-Human clinical trial in the United States.
GE Healthcare and SonoMotion establish a strategic partnership and sign a definitive OEM agreement and co-development agreement.
SonoMotion receives a $1.0M SBIR Commercial Readiness Program grant from the NIH for the development of Stone Clear™.
SonoMotion closes on a $4.6M Series-A round led by MedVenture Partners Inc. and with a significant participation by Bioventures Investors.
SonoMotion secures a $1.75M SBIR FastTrack grant from the NIH for the development of Break Wave™.
SonoMotion receives a $350,000 grant from NASA and NSBRI to accelerate development of Break Wave™.